Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors.
Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, Sunami K, Kubo T, Kohno T, Akihiko Y, Yamamoto N, Yonemori K. Takeyasu Y, et al. Among authors: shimoi t. JCO Precis Oncol. 2021 May 3;5:PO.20.00383. doi: 10.1200/PO.20.00383. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34036223 Free PMC article.
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Nishikawa T, et al. Among authors: shimoi t. Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5. Cancer Sci. 2017. PMID: 28665051 Free PMC article. Clinical Trial.
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K. Bun S, et al. Among authors: shimoi t. Invest New Drugs. 2018 Feb;36(1):151-155. doi: 10.1007/s10637-017-0487-3. Epub 2017 Jul 21. Invest New Drugs. 2018. PMID: 28733700 Clinical Trial.
Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.
Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K. Sasada S, et al. Among authors: shimoi t. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2146-2147. doi: 10.1007/s00259-017-3781-6. Epub 2017 Aug 3. Eur J Nucl Med Mol Imaging. 2017. PMID: 28770275 No abstract available.
116 results